MDGL · Madrigal Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $12.50B |
| P/E | — |
| Float | 21.69M |
| Beta | -1.10 |
| Volatility | 27.4% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 74 |
| Price | 541.08 |
| Change | −0.01% |
| Prev Close | 541.12 |
| Open | 536.82 |
| Day Low | 535.60 |
| Day High | 547.92 |
| Avg Vol | 0 |
| Avg $ Vol | $107.9M |
| 52W High | 615.00 |
| 52W Low | 393.61 |
| 52W Pos | 66.6% |
| From High | −12.02% |
| From Low | +37.47% |
| Max DD 1Y | −29.36% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +2.31% |
| SMA 50 | +2.17% |
| SMA 200 | +5.00% |
| RSI (14) | 55.0 |
| Vol 30D | 51.1% |
| Vol 90D | 44.9% |
| 1Y Range | 394–615 |
| Daily bars | 507 |
| Perf Week | +1.37% |
| Perf Month | +6.02% |
| Perf Quarter | +11.11% |
| Perf Half Y | +25.01% |
| Perf Year | +25.48% |
| Perf YTD | −8.89% |
| Prev Day | −0.01% |
| Clavix | B |
| Debt / Eq | 0.56 |
| Curr Ratio | 4.01 |
| Int Cover | -68.3× |
| FCF Margin | 9.3% |
| Rev Growth | +71.2% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 14 / 35 |
Clavix risk grade
regraded every trading dayMDGL grades B, 74 of 100. Steadiest on Macro Resilience (68), most exposed on Price Stability (53, mixed). 4 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 14 of 35 in Biotechnology by Clavix score.
How rough the ride is
| MDGL | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | −1.10 | 0.50 |
| Volatilityannualized | 27.4% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −29.4% | — |
| Typical daily movemedian absolute daily change | 1.40% | — |
| Days beyond ±3%of the last 252 sessions | 5522% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MDGL | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | −1.10 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MDGL | |
|---|---|
| 1 week | +1.4% |
| 1 month | +6.0% |
| Year to date | −8.9% |
| 1 year | +25.5% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MDGL | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 2 Jul |
| Average score0 most bearish, 100 most bullish | 65 |
| Bullish · bearisharticles above 60 · below 40 | 24 · 1 |
| Directionarticles whose tone is improving vs worsening | 24 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| MDGL | |
|---|---|
| Revenue growthyear over year | +71.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | MDGL | Sector spread | Median |
|---|---|---|---|
| Beta | -1.10 | 0.50 | |
| Volatility | 27.4% | 13.2% | |
| Debt / equity | 0.56 | 0.24 | |
| Current ratio | 4.01 | 3.73 | |
| FCF margin | 9.3% | 29.1% | |
| Interest coverage | -68.3× | -0.2× |
Recent news
most recent scored articles · the chip is the article’s score · click to openThe article examines what would need to happen for Madrigal Pharmaceuticals (MDGL) stock to take off, highlighting two potential catalysts: expansion of Rezdiffra's market into MASH cirrhosis patients, and growth of Madrigal's pipeline to reduce reliance on Rezdiffra.
An opinion piece outlines three things that would need to happen for Madrigal Pharmaceuticals stock to rise: continued Rezdiffra sales growth, FDA approval expansion to MASH cirrhosis patients (roughly 245,000 diagnosed U.S. patients under specialist care with no approved treatment), and proof of additional value beyond Rezdiffra. Rezdiffra, a once-daily pill, is currently approved for moderate-to-advanced liver scarring but not cirrhosis.
BlackRock Inc. took a new position in Madrigal Pharmaceuticals (MDGL) during the second quarter, buying 1,200,770 shares, according to its 13F filing with the SEC. A 13F is a quarterly disclosure required of large investment managers showing what stocks they bought or sold.
Madrigal Pharmaceuticals reported that Rezdiffra achieved a $1.3 billion run rate in Q2 2026 with strong commercial growth, while the company expanded its MASH development pipeline and prepared for upcoming clinical catalysts.
Madrigal Pharmaceuticals said its MASH drug Rezdiffra reached a $1.3 billion annual sales run rate in the second quarter of 2026, while the company expanded its development pipeline around the therapy and prepared for several potential clinical milestones.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| HALO | Halozyme Therapeutics Inc | B | $12.51B | 30.24 | 0.96 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $12.20B | — | 1.30 | Compare |
| EXEL | Exelixis Inc | B+ | $14.62B | 16.99 | 0.48 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $14.63B | — | 0.96 | Compare |
| KRYS | Krystal Biotech Inc | B | $10.60B | 43.91 | 0.55 | Compare |
| CYTK | Cytokinetics Inc | B | $10.11B | — | 0.39 | Compare |
| NBIX | Neurocrine Biosciences Inc | B | $15.82B | 22.42 | 0.36 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $9.65B | — | 0.38 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.